Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China.
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China.
Comb Chem High Throughput Screen. 2023;26(2):347-361. doi: 10.2174/1386207325666220421102117.
The clinical value of pyroptosis-related genes (PRGs) in lung adenocarcinoma (LUAD) remains obscure.
The study attempts to explore PRGs in LUAD, which will enable an understanding of LUAD from the perspective of PRGs.
Lung adenocarcinoma patients were diagnosed using pathology, and their clinical information was collected from several public databases. A PRGs prognostic signature (PPS) for LUAD patients was established based on a multivariate Cox regression analysis. The differential expression of PRGs was identified using standardized mean differences in 6,958 samples. The area under the curve (AUC) was used to evaluate the predictive effects of the PPS to determine the survival rate of LUAD patients. Decision curve analysis was utilized to assess the clinical significance of the PPS in LUAD.
The PPS consists of five PRGs, namely CASP3, CASP9, GSDMB, NLRP1, and TNF. The prognostic effect of the PPS is evident in all the predicted one-, three-, and five-year survival rates (AUCs ≥ 0.58). The PPS represents an independent risk factor for the prognosis of LUAD patients (hazard ratio > 1; 95% confidence interval excluding 1). The PPS risk score can predict the prognosis of LUAD patients more accurately than PRGs of the PPS and multiple clinical parameters, such as age, tumor stage, and clinical stage. The decision curve analysis revealed that the nomogram based on the PPS and clinical parameters might result in better clinical decisions.
The PPS makes it feasible to distinguish LUAD from non-LUAD. Thus, the underlying significance of the PPS in distinguishing LUAD from non-LUAD is promising.
细胞焦亡相关基因（PRGs）在肺腺癌（LUAD）中的临床价值尚不清楚。
本研究试图探索 LUAD 中的 PRGs，以期从 PRGs 的角度来理解 LUAD。
通过病理学诊断 LUAD 患者，并从多个公共数据库中收集其临床信息。基于多变量 Cox 回归分析，建立 LUAD 患者的 PRGs 预后签名（PPS）。使用 6958 个样本的标准化均数差来鉴定 PRGs 的差异表达。通过曲线下面积（AUC）评估 PPS 对 LUAD 患者生存率的预测效果。利用决策曲线分析评估 PPS 在 LUAD 中的临床意义。
PPS 由五个 PRGs 组成，分别为 CASP3、CASP9、GSDMB、NLRP1 和 TNF。PPS 的预后效果在所有预测的 1 年、3 年和 5 年生存率（AUC≥0.58）中均显著。PPS 是 LUAD 患者预后的独立危险因素（风险比>1；95%置信区间不包括 1）。PPS 风险评分可以比 PPS 的 PRGs 和多个临床参数（如年龄、肿瘤分期和临床分期）更准确地预测 LUAD 患者的预后。决策曲线分析表明，基于 PPS 和临床参数的列线图可能会带来更好的临床决策。
PPS 可区分 LUAD 和非 LUAD。因此，PPS 在区分 LUAD 和非 LUAD 中的潜在意义具有广阔的应用前景。
